← Back to Analyst Consensus 
IBIO Buy
iBio, Inc.
Current Price —
Implied Upside —
Analysts 15
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 10, 2026 (15 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 17, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Jul 2, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Jun 8, 2026 | Raymond James | initiate | — → Outperform | — | 54% |
| Apr 9, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Mar 18, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Mar 3, 2026 | Jones Trading | initiate | — → Buy | — | 50% |
| Feb 12, 2026 | Chardan Capital | maintain | Buy → Buy | $5 | 47% |
| Oct 21, 2025 | Oppenheimer | initiate | — → Outperform | $5 | 52% |
| Oct 17, 2025 | Leerink Partners | initiate | — → Outperform | $2 | 51% |
| Jun 25, 2025 | Chardan Capital | maintain | Buy → Buy | $5 | 47% |
| May 6, 2025 | Chardan Capital | maintain | Buy → Buy | $5 | 47% |
| May 5, 2025 | Chardan Capital | maintain | Buy → Buy | $5 | 47% |
| Dec 17, 2024 | LUCID CAPITAL MARKETS | initiate | — → Buy | $6 | 32% |
| Jul 22, 2024 | Brookline Capital | initiate | — → Buy | $3.6 | 38% |
| Jun 3, 2024 | Chardan Capital | maintain | Buy → Buy | $5 | 47% |
| May 28, 2024 | Chardan Capital | initiate | — → Buy | $5 | 47% |
Price Target Trend
Apr 8, 2026 Oct 26, 2026
EPS Estimates
+1y —
0y —
+1q —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days